SynthesisJournal of orthopaedic surgery and research2025
Meridian-Sinew Release Therapy as an adjunctive treatment for gouty arthritis: a systematic review and meta-analysis.
Synthesis in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study aims to evaluate the efficacy and safety of Meridian-Sinew Release Therapy (MSRT) combined with conventional Western medicine (MSRTW) in the treatment of gouty arthritis (GA) and to provide scientific evidence for clinical practice.
methodsA comprehensive search of both Chinese and English literature databases was conducted to identify randomized controlled trials (RCTs) that met the inclusion criteria. The study compared MSRTW to Western medicine treatment (WM) alone. The primary outcome was changes in serum uric acid levels (SUA), and secondary outcomes included Visual Analog Scale (VAS) pain scores, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). Additionally, the safety and incidence of adverse events were analyzed.
resultsA total of 6 RCTs involving 376 participants were included. Meta-analysis demonstrated that the MSRTW group was significantly more effective than the WM group in reducing SUA levels (MD = -99.94, P < 0.001), relieving pain (VAS score: MD = -1.50, P < 0.001), and improving ESR and CRP levels. Additionally, fewer adverse events were reported in the MSRTW group, indicating good safety. Sensitivity analyses confirmed the robustness of the results. Subgroup analyses suggested that treatment duration, gender, and the use of urate-lowering therapy or colchicine may be potential sources of heterogeneity.
conclusionMSRT, as an adjunct therapy, may offer clinical benefits in managing gouty arthritis by reducing urate deposition, relieving inflammation, and improving joint function with good safety. However, due to the limited sample size and variability among studies, further high-quality, multi-center trials are needed to confirm its long-term efficacy and underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.